ClinicaliQ Trial Snapshot
- Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) — Recruiting • Phase II • Cardiology / Cardiovascular • NCT06122779.
- Drug being tested: BMS-986435/MYK-224, a novel therapeutic agent being evaluated for safety, tolerability, and pharmacokinetic exposure in patients with symptomatic HFpEF.
- Patient eligibility: The trial recruits symptomatic patients with Heart Failure with Preserved Ejection Fraction (HFpEF)—a condition affecting approximately 50% of heart failure cases where the heart's pumping function remains relatively normal despite functional impairment.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
Eligibility Snapshot
- - Adult participants with stable, symptomatic HFpEF with a normal heart pumping ability.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.